News

Study findings suggest that neither olaparib monotherapy or olaparib plus cediranib increased progression-free survival when compared with platinum-based chemotherapy in women with high-grade serous or endometroid ovarian cancer sensitive to...

Avelumab and atezolizumab may have limited impact on the clinical outcome of patients with newly diagnosed ovarian carcinoma, according to recent study findings.

Among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, only about half underwent adequate lymph node dissection and received adjuvant chemotherapy, despite guideline indications.

Study findings shed light on survival outcomes among vulnerable groups of pre-treated patients with advanced NSCLC receiving immunotherapy, who are often excluded from real-world clinical trials.

Findings from a cost-effectiveness analysis demonstrate that there is significant cost associated with the use of 3 years of adjuvant osimertinib for patients with resected EGFR-mutant NSCLC.

Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though

A population-based cohort analysis on patients who were diagnosed with mantle cell lymphoma found that overall survival and lymphoma-specific survival may improve with BTK inhibitors.

Among patients with ovarian cancer who received first-line treatment with bevacizumab, clinical outcomes and tolerability are consistent in the real-world setting and clinical trials.

Findings from a real-world study suggest the addition of pertuzumab to trastuzumab and chemotherapy improves safety and OS for patients with metastatic breast cancer.

Study findings show breast cancer episodes in older women with distant metastases frequently exceeded the target price under the OCM payment methodology.